Intraarticular injection of dexamethasone (DEX) accelerates cartilage degradation due to the suppression of chondrocyte proliferation and extracellular matrix formation. The present study first demonstrated the interaction between DEX and TGF , a potent growth factor for cultured rat articular chondrocytes (CRAC), and then investigated the molecular mechanism by which DEX counteracts TGF -induced chondrocyte proliferation and differentiation through the regulation of AP-1 activity. DEX reduced serum-deprived and TGF -stimulated cell growth and [
Introduction
Intraarticular injection of dexamethasone (DEX), an antiinflammatory glucocorticoid, is commonly used to relieve clinical symptoms in affected osteoarthritic joints. Various studies have demonstrated that DEX inhibits the synthesis of matrix metalloproteases and inflammatory cytokines in experimental osteoarthritis (OA) models. [1] [2] [3] [4] [5] [6] However, it is widely recognized that repeated articular injection of DEX potentially worsens osteoarthrosis by accelerating cartilage degradation. Another undesirable functional property of DEX is suppression of de novo protein synthesis of extracellular matrix, such as type II collagen and proteoglycan. 3, 6 The molecular mechanism of DEX-involved transcriptional regulation has been identified in the past decade. DEX acts by binding to homometric glucocorticoid receptor (GR) and transactivates target genes through a glucocorticoid response element. DEX also exerts a negative regulation of expression of several genes through the TPA responsive element (TRE) by antagonizing AP-1, a transcriptional factor composed of Fos (c-Fos, Fra-1 and FosB) and Jun (c-Jun, JunB and JunD) families. [7] [8] [9] Although the exact mechanism of this negative regulation is not completely understood, and there are some contradicting data, it is likely that DEX antagonizes AP-1 by disrupting protein-protein interaction or by altering the functional domains of Fos and Jun. [10] [11] [12] [13] TGF is a growth factor stored abundantly in extracellular matrix in inactive form, 14, 15 but once released from the matrix in response to a variety of stimuli, TGF plays an important role in the process of cartilage repair. 16, 17 In articular chondrocytes, TGF stimulates cell growth and production of extracellular matrix. [18] [19] [20] TGF exerts its action via a heterometric complex of serine/threonine kinase type I and type II TGF receptors. After binding to the receptors, TGF transmits signals through MAPK cascade and Smad pathway. [21] [22] [23] We have recently demonstrated that among the downstream cascades of MAPK, ERK activation is required for TGF -induced cell growth in cultured rat articular chondrocytes (CRAC). 24 We also demonstrated that TGF immediately transactivates c-fos gene expression through the serum responsive element (SRE). 25 Despite the long-term use of DEX intraarticularly, little is known about the molecular mechanism underlying DEX-mediated inhibition of chondrocyte cell growth and matrix synthesis, including the interaction of DEX with TGF . In this study, we first showed that DEX inhibited TGF -induced cell growth and type II collagen expression in CRAC. To clarify the mechanism of the interaction between DEX and TGF , we focused on the regulation of AP-1 activity and provided evidence for AP-1 serving as the potential target of the interaction. We also demonstrated that TGF -induced ERK activation of MAPK cascade, but not the Smad pathway, is suppressed by DEX. We propose here that DEX counteracts TGF -induced cell proliferation and differentiation, presumably by interrupting ERKmediated c-fos gene expression and subsequent AP-1 complex formation.
Materials and methods

MATERIALS
Five-week-old male Sprague-Dawley (SD) rats were purchased from Charles River Laboratories (Shizuoka, Japan). Lipofectin Reagent, fetal bovine serum (FBS) and DMEM were obtained from Gibco Oriental (Tokyo, Japan). Recombinant human TGF 1 was from AUSTRAL Biologicals (San Ramon, CA, U.S.A.). The cell culture plates were from Falcon (Lincoln Park, NY, U.S.A.), Corning (Corning, NY, U.S.A.) and Costar (Cambridge, MA, U.S.A.). Luciferase Assay System and -Galactosidase Enzyme Assay were from Promega (Tokyo, Japan). PathDetect Elk1 transReporting System and pAP1-luc were from STRATAGENE (La Jolla, CA, U.S.A.). PhosphoPlus p44/42 MAPK(Tyr204) antibody kit and specific MEK1 Inhibitor (PD98059) were purchased from New England Biolabs (Beverly, MA, U.S.A.). All other reagents were obtained from Sigma Chemical Co. (St Louis, MO, U.S.A.).
CELL CULTURES
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of Nagasaki University Medical School. Chondrocytes were isolated from rat articular cartilage as described previously. 18 Isolated chondrocytes were cultured with DMEM which contained 10% FBS, and passaged once for the experiments.
CELL COUNTING
Using a Cell Counting Kit (DOJINDO, Japan), the cell growth of CRAC was evaluated by the WST-1 method as previously described. 24 Briefly, 1×10 3 chondrocytes were seeded in a 96-well plate and cultured for 48 h. After serum starvation for 24 h, the cells were incubated with or without TGF -1 and DEX together with a tetrazolium bromide, and absorbance at 405 nm wavelength was measured at 12, 24 and 36 h after stimulation. RNA extraction and the following Northern blot analysis were performed as described previously. 18 Twenty micrograms of total RNA was electrophoresed in a denatured condition, blotted on nylon membrane and subjected to hybridization with specific probes for rat 1 type II collagen and c-fos prepared as previously described. 18, 25 P3TP, AP-1 AND COL2A1 LUCIFERASE ASSAY CRAC at 80% confluence were transiently transfected by Lipofectin as described previously. 24 Twenty-four hours later, the cells were further incubated for 24 h with or without TGF . Cell extracts were then prepared and luciferase activity was measured by a luminometer (TD-2020, Turner Designs Instrument, Sunnyvale, CA, U.S.A.). To estimate the transfection efficiency, the pCMV5-GAL vector was cotransfected in each experiment, and -galactosidase activity was measured at 600 nm wavelength with ONPG as described elsewhere. 26 
TRANS-REPORTER ASSAY OF ELK1
To detect endogenous ERK activity in vivo, the pFAElk1 vector that expresses a fusion protein of the functional domain of Elk1 following GAL4 DNA binding domain was transiently transfected in CRAC together with the reporter vector pFR-Luc which contains a GAL4-response element upstream of the luciferase gene. 24 Luciferase activity was then measured as described above.
IN VITRO KINASE ASSAY OF ERK
ERK activity was estimated by in vitro kinase assay as described previously. 24 Kinase reaction was performed at 30°C for 30 min in the presence of cold ATP together with Elk1 fused to GST protein. Samples were immunoprecipitated with glutathione-Sepharose (Pharmacia) and subjected to SDS-PAGE. Phosphorylated Elk-1 was immunodetected on PVDF membranes with phosphospecific Elk1 (Ser 383) antibody.
Results
DEX-INDUCED SUPPRESSION OF CRAC CELL GROWTH
DEX is thought to inhibit the growth of articular chondrocytes under in vivo and in vitro conditions. To examine whether such suppressive effect could be reproduced in our culture system, CRAC were incubated with three different concentrations of DEX, with or without TGF , and cell number was monitored for up to 36 h by WST assay. The cell number of control CRAC at 12 h increased about 1.4-fold relative to the starting point, and remained stable at that level until 36 h [ Fig. 1(a) ]. Incubation with DEX significantly reduced cell growth in a dose-dependent manner at all time points. TGF -stimulated cell proliferation was also suppressed by DEX. Incubation with TGF alone for 36 h increased the cell number to 2.2-fold of the control level, whereas co-incubation with DEX reduced TGF -induced cell growth in a dose-dependent manner, whereby the highest concentration of DEX (10 −4 M) reduced TGFinduced proliferation to the control levels. Suppression of DNA synthesis by DEX was confirmed by [ 3 H]-thymidine incorporation assay. Incubation of CRAC with TGF stimulated DNA synthesis to 4.5-fold of control, but co-culture with DEX resulted in a dose-dependent inhibition of thymidine incorporation [ Fig. 1(b) ]. Consistently, the highest concentration (10 −4 M), DEX completely abolished TGF -stimulated DNA synthesis.
INHIBITION OF EXPRESSION OF TYPE II COLLAGEN BY DEX
To examine the effects of DEX on chondrocyte differentiation, we determined the expression of type II collagen by Northern blotting. For this purpose, 24 h serum-deprived CRAC were incubated with or without TGF and DEX for 24 h. Incubation of CRAC with TGF resulted in about 3-fold increase in the expression of type II collagen, whereas incubation with DEX reduced mRNA expression to about 20% of the control [ Fig. 2(a) ]. Furthermore, the increased expression of collagen mRNA by TGF was significantly reduced to about 70% of TGF alone by co-incubation with DEX. DEX-induced inhibition of type II collagen mRNA expression was confirmed by the promoter analysis using a luciferase vector which contained four copies of a 48-bp enhancer element from the first intron of pro 1(II) collagen gene. CRAC transiently transfected with this construct together with pCMV5-GAL were incubated with or without DEX together with TGF for 24 h. TGF stimulation caused about 3.5-fold increase in luciferase activity [ Fig. 2(b) ]. Incubation with DEX, however, resulted in a dose-dependent inhibition of TGF -activated induction, although the basal level did not change significantly. The highest concentration of DEX (10 −4 M) resulted in a complete inhibition of TGF -induced activation. Considered together, these results indicate that DEX acts as static factor for chondrocyte proliferation and differentiation. To determine the mechanism of DEX-induced suppression of cell growth and expression of type II collagen in CRAC, we focused on the regulation of AP-1 activity, one of DEX targets. For this purpose, a reporter construct containing seven copies of the 6-bp AP-1 binding site was transfected into CRAC and the cells were incubated with or without DEX together with TGF for 24 h. Incubation of CRAC with TGF resulted in a dose-dependent increase of luciferase activity [ Fig. 3(a) ]. Co-incubation with DEX, however, resulted in a significant decrease of the TGFinduced reporter activity in a dose-dependent manner, while the basal level was not affected. We also examined DEX inhibition of AP-1 activity using 3TP-luc which contains a PAI-1 and three copies of TRE. 27 Consistently, DEX, at concentrations higher than 10 −7 M decreased TGFinduced luciferase activity in a dose-dependent manner [ Fig. 3(b) ]. These results indicate that AP-1 is a candidate target molecule involved in the antagonistic effect of DEX on TGF action in CRAC.
REGULATION OF SMAD AND MAPK PATHWAYS BY DEX
In CRAC, TGF transduces intracellular signaling through Smad as well as MEK-ERK pathway; the latter cascade can transactivate the c-fos gene. Since c-Fos is a component of AP-1 together with c-Jun, it is possible that the inhibition of AP-1 activity by DEX was due to the interruption of signal transmission to the ERK pathway. However, it is also possible that DEX interferes with the Smad pathway, which alone can transactivate TRE. Therefore, we investigated both possibilities using GAL4-Elk1 and ARE-luc. We first examined the effect of DEX on ERK activity by GAL4-Elk1 assay which allows evaluation of the endogenous activity of ERK. Consistent with 3TP-luc, luciferase activity induced by TGF was inhibited by DEX in a dose-dependent manner, while the basal level was not affected significantly [ Fig. 4(a) ]. Involvement of the Smad pathway was investigated by using ARE-luc, which contains three copies of activin-responsive elements. 28 For the activation of ARE-luc, expression vectors of Fast1, a Smad2 and Smad3 binding transcriptional factor, were cotransfected to CRAC. Although transfection with ARE alone failed to be activated (data not shown), co-transfection with Fast1 induced a significant increase of luciferase activity, and in the presence of TGF the activity was stimulated about seven-fold of the control. In contrast to Elk-1, DEX did not affect either the basal or TGFstimulated luciferase activities [ Fig. 4(b) ]. These results indicate that the MEK-ERK cascade of MAP kinases but not the Smad pathway could be a potential target of DEX-dependent inhibition of AP-1 activity.
DEX INHIBITION OF ERK ACTIVITY AND C-FOS GENE EXPRESSION
To determine whether DEX-dependent inhibition of ERK activity occurred in an early phase following TGF stimulation, in vitro kinase assay was performed using the cell lysate pretreated with various concentrations of DEX for 1 h and stimulated with TGF for 5 min. Consistent with our previous findings, TGF stimulation caused a rapid activation of ERK [ Fig. 5(a) ]. Pre-incubation with DEX, however, dramatically reduced TGF -induced kinase activity from the lowest concentration, and completely abrogated ERK activity at 10 −7 and 10 −4 M concentrations. Similar repression was also observed by Northern blot study of c-fos gene expression, a target gene for MEK-ERK pathway. Pre-treatment with various concentrations of DEX resulted in a dose-dependent decrease of TGF -induced mRNA expression, although even the highest concentration of DEX (10 −4 M) reduced the expression about 50% of the control [ Fig. 5(b) ]. Together with GAL4-Elk1 assay, however, these results indicate that DEX antagonizes TGF -induced MEK-ERK activation and subsequent c-fos expression.
PD98059 INHIBITS TGF -ENHANCED DNA SYNTHESIS AND PROMOTER ACTIVITY OF TYPE II COLLAGEN
The functional involvement of MEK-ERK pathway in DNA synthesis and expression of type II collagen was evaluated using PD98059, an inhibitor of MEK. For this, CRAC were incubated with various concentrations of PD98059 with or without TGF , and [ 3 H]-thymidine was incorporated for the last 5 h. As expected, TGF -stimulated DNA synthesis was inhibited by PD98059 in a dosedependent manner, while the basal levels were only affected minimally [ Fig. 6(a)] . Similarly, the luciferase activity of type II collagen reporter construct stimulated by TGF was reduced by PD98059 in a dose-dependent manner, whereas the basal level did not change [ Fig. 6(b) ].
Discussion
In the present study, we first examined the interaction between DEX and TGF on cell growth and the expression of ( )1 type II collagen mRNA using CRAC. Consistent with previous studies, 29 high concentrations of DEX (>10 −7 M) retained CRAC to static state even in the presence of TGF . DEX also blocked the expression of type II collagen, a marker for chondrocyte differentiation, with concomitant suppression of the enhancer activity. These results, combined with the previous findings that DEX inhibits the expression of types II and IX collagens and proteoglycan, 3, 6 indicate that DEX in general, is likely to act as an inhibitor of chondrocyte cell growth and differentiation.
To investigate the mechanism of DEX-induced suppression of CRAC proliferation and differentiation, we focused on the regulation of AP-1 activity. DEX has been shown to trans-repress several TRE containing genes. [7] [8] [9] Although still controversial, GR seems to specifically oppose the regulatory action by modulating the protein-protein interaction of c-Fos and c-Jun. [10] [11] [12] [13] It appears that GR can bind directly with c-Fos and c-Jun, and interfere with their homo-or hetero-dimerization. In our study, the activities of both AP-1 and 3TP-luc reporters were suppressed by DEX, indicating that DEX counteracts TGF -induced cell proliferation and differentiation through AP-1 activity. In CRAC, however, we demonstrated that the interaction occurred within an early phase of TGF signaling cascade rather than targeting c-Fos and/or c-Jun itself (see below).
It is well known that activated ERK phosphorylates Elk1 that leads to transactivation of the c-fos gene expression via SRE together with ternary complex factor. 30 Overexpression of c-Fos contributes to AP-1 activation by complex formation with pre-existing c-Jun. We have previously demonstrated in CRAC that TGF transmits signals through only ERK but not JNK or p38MAPK of MAPK cascades, and transactivates c-fos gene through SRE. 24, 25 Furthermore, this specific ERK activation is required for TGF -induced cell proliferation. 24 On the other hand, it has recently been demonstrated that Smad3 could transactivate AP-1 sites by direct binding to DNA, and that this transactivation is enhanced by the direct interaction of Smad3 with Smad4, c-Fos and c-Jun. 31 These findings suggest that DEX exerts its negative effect by inhibiting ERK and/or Smad signaling cascades of TGF . Therefore, we investigated the possible involvement of these pathways in DEX-dependent inhibition of AP-1 activity, using Elk-1-GAL4 and ARE-luc which reflect ERK and Smad activities, respectively. Our results that DEX reduced ERK activation but not that of ARE-luc, suggest that DEX selectively inhibits TGF -induced MEK-ERK pathway but not Smad pathway. Indeed, in in vitro kinase assay for ERK, pretreatment of CRAC with DEX blocked Elk1 phosphorylation. Furthermore, c-fos expression induced by TGF was also repressed as well. However, TGF -induced MEK activation was inhibited by lower concentrations of DEX compared with c-fos expression, suggesting that in addition to MEK-ERK, other TGF receptor signaling pathways which are independent of the cross-talk with DEX, may be involved in the induction of c-fos gene. Alternatively, these results implicate that DEX acts negatively toward TGFinduced AP-1 activation through a selective inhibition of MEK-ERK pathway. Although the significance of ERK activation for AP-1 activity has not yet been completely clarified in CRAC, the reduced expression of c-Fos may cause an imbalance of Fos-Jun complex formation, resulting in a transrepression of TRE (Fig. 7) . Further studies including the identification of the exact target molecules of DEX within MAPK are necessary to clarify the mechanism of DEX-dependent inhibition of AP-1 activity in CRAC.
The enhancer element present in the first intron of type II collagen contains cis-elements for Sox9, Sox6 and L-Sox5, all of which are expressed predominantly in developing chondrocytes and are required for full activation of the collagen gene. [32] [33] [34] Since there is no AP-1 binding site in this region, DEX may exert its negative effect through alteration of the functional properties of these molecules or by transrepression of upstream regulators required for the activation of collagen gene, rather than acting directly on this enhancer element. Similarly, it is possible that DEX suppression of TGF -induced cell growth was not only due to the inhibition of MEK-ERK pathway. Other target molecules may be required for the initiation of DNA synthesis and subsequent cell proliferation. In the present study, the basal level of type II collagen expression was strongly diminished by DEX compared with TGF -induced expression, while the basal levels in the promoter analysis were less affected even in the presence of high concentrations of DEX. This discrepancy may be explained by a mechanism in which TGF increases both the mRNA stability and promoter activity for type II collagen whereas DEX primarily affects the stability of the mRNA, and there is an extensive literature describing these functional properties in DEX and TGF . 35, 36 However, DNA synthesis and the promoter activity of type II collagen were blocked by MEK inhibitor in a similar manner by DEX, suggesting that MEK-ERK pathway could be, at least initially, the target molecule for DEX to inhibit DNA synthesis and differentiation of CRAC.
In conclusion, we demonstrated in the present study that DEX antagonized TGF -induced cell proliferation and the expression of ( )1 type II collagen in CRAC, presumably through a trans-repression machinery leading to AP-1, whereby the selective inhibition of ERK pathway of MAPK cascade may be integrated in the negative regulation of AP-1 by DEX. 
